It looks like you're using an unsecure version of Internet Explorer. Using an outdated browser makes your computer unsafe. For the best and safest website experience, please update your
or please use
or
Registration | Diabetes on the Net
Your web browser is out of date.
For your security and improved experience online, please update your browser.
This promotional webinar was initiated and fully funded by AstraZeneca. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this webinar was provided by OmniaMed Communications.
Forxiga® (dapagliflozin) for managing heart failure in people with or without type 2 diabetes: New NICE guidance
This promotional webinar was initiated and fully funded by AstraZeneca. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast. Editorial support for this webinar was provided by OmniaMed Communications.
We look forward to welcoming you online. You will receive a confirmation email shortly and we will send you a reminder email closer to the start of the broadcast.
Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective
XX September 2020
Complete the registration form
XX Month 2020
Complete the registration form
We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing
your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.